Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascentage Pharma Group International (NASDAQ: AAPG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. Ascentage Pharma files annual reports on Form 20‑F and current reports on Form 6‑K under the Securities Exchange Act of 1934, reflecting its status as a NASDAQ‑listed biopharmaceutical company with operations in oncology and hematology.
Recent Form 6‑K filings have furnished press releases on a range of material topics, including pivotal Phase II and Phase III clinical data for Lisaftoclax and olverembatinib, regulatory clearances from the U.S. FDA and EMA for global registrational studies such as POLARIS‑1 and GLORA, publication of olverembatinib data in gastrointestinal stromal tumors, investor conference participation, interim financial results and business updates, and corporate governance items such as indemnification agreements and interest payments related to top‑up placements. These filings help investors understand the progress of Ascentage Pharma’s apoptotic pathway inhibitors, BCR‑ABL1 inhibitor programs, and protein degrader pipeline.
On Stock Titan, each new AAPG filing is captured from EDGAR and presented with AI‑generated highlights to explain the context and key points in clear language. Users can review Form 6‑K submissions related to clinical milestones, financing activities, and board decisions, and can connect these disclosures to the company’s broader oncology strategy. While Ascentage Pharma’s core SEC reporting currently emphasizes 6‑K updates, investors can also reference its Form 20‑F annual report for a more detailed discussion of risk factors, business overview, and financial statements.
In addition, this page offers quick access to historical filings so that readers can trace how Ascentage Pharma’s hematology and solid tumor programs, global partnerships, and capital markets activities have evolved over time. AI‑assisted summaries help reduce the time needed to interpret lengthy documents, highlighting items such as major clinical trial announcements, regulatory interactions, and key corporate actions disclosed in AAPG’s SEC submissions.
Ascentage Pharma Group International filed a Form 6-K furnishing a press release summarizing its 2025 milestones and 2026 global innovation strategy in cancer and hematologic diseases. The company highlights two commercialized hematology products, Olverembatinib (a third-generation BCR-ABL1 inhibitor) and Lisaftoclax (a Bcl-2 inhibitor), as dual growth engines anchored in the China market and supported by National Reimbursement Drug List coverage for Olverembatinib.
Ascentage Pharma reports U.S. FDA IND clearance for APG-3288, a next-generation BTK protein degrader using its PROTAC platform, initiating its clinical development in targeted protein degradation. The pipeline update notes multiple global registrational Phase III trials progressing in chronic myeloid leukemia, Ph+ ALL, SDH-deficient GIST, CLL/SLL, AML and higher-risk MDS, along with earlier-stage programs such as APG-5918, APG-2449, Alrizomadlin and Pelcitoclax. For 2026, the company points to planned advancement of Phase III studies, broader commercialization with coverage across 1,500 hospitals, and key early-stage readouts, while emphasizing that its main investigational agents have not been approved by the U.S. FDA.
Ascentage Pharma Group International submitted a Form 6-K stating that on December 17, 2025 it issued a press release titled “Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference.” The report’s primary purpose is to furnish this press release as Exhibit 99.1 for U.S. investors.
Ascentage Pharma Group International submitted a Form 6-K as a foreign private issuer for November 2025. The report mainly notes that on November 24, 2025 the company issued a press release titled “Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy”. A copy of this press release is furnished as Exhibit 99.1, making the scientific and clinical update available to investors through the U.S. disclosure system.
Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer to furnish a company press release. The filing notes that on November 19, 2025, the company issued a release titled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025.” The press release itself is attached as Exhibit 99.1 to the report. This Form 6-K does not present financial results or transaction details; it primarily serves to formally provide the investor conference announcement to the market.
Ascentage Pharma Group International filed a Form 6-K noting plans to present clinical data at the 2025 American Society of Hematology (ASH) Annual Meeting. The company furnished two press releases dated November 3, 2025 and a Hong Kong Stock Exchange announcement dated November 4, 2025 as Exhibits 99.1, 99.2, and 99.3.
The disclosures state Ascentage will share results from multiple studies of olverembatinib and lisaftoclax, and additional data on APG-5918. One of the presentations has been selected for an oral report.
Ascentage Pharma Group International (AAPG) filed a Form 6-K that furnishes a press release titled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025.” The release is included as Exhibit 99.1. The filing notes the company’s plan to engage investors at two conferences in November 2025 and provides the press release for additional details.
Ascentage Pharma Group International filed a Form S-8 to register the issuance of an additional 5,800,000 ordinary shares of common stock, par value US$0.0001 per share, under its Amended 2022 Restricted Share Unit Scheme. This expands the pool of shares available for equity awards to employees and other eligible participants.
The company had previously registered 5,272,695 ordinary shares for the original 2022 Restricted Share Unit Scheme on a prior Form S-8. The new filing incorporates that earlier registration by reference and includes customary exhibits such as legal opinions, auditor consents and the amended RSU scheme document. The registration statement is signed on behalf of the company by its Chief Executive Officer, Dajun Yang.
FAQ
What is the current stock price of Ascentage Pharma Group International (AAPG)?
What is the market cap of Ascentage Pharma Group International (AAPG)?
